A Behavioral Economic Approach to Improving Human Papillomavirus Vaccination

被引:15
|
作者
Caskey, Rachel [1 ,2 ]
Sherman, E. Grace [3 ]
Beskin, Kera [3 ]
Rapport, Rebecca [3 ]
Xia, Yinglin [2 ]
Schwartz, Alan [4 ]
机构
[1] Univ Illinois, Dept Pediat, 840 S Wood St M-C 718, Chicago, IL 60302 USA
[2] Univ Illinois, Dept Med, 840 S Wood St M-C 718, Chicago, IL 60302 USA
[3] Univ Illinois, Sch Publ Hlth, Chicago, IL 60302 USA
[4] Univ Illinois, Dept Med Educ, Chicago, IL 60302 USA
基金
美国国家卫生研究院;
关键词
Human papillomavirus; Vaccination; Immunization; Adolescent immunization; Prevention; UNITED-STATES; INTRAEPITHELIAL NEOPLASIA; FINANCIAL INCENTIVES; QUADRIVALENT VACCINE; CONTROLLED-TRIAL; HPV INFECTION; PREVALENCE; SMOKING; CANCER; STUDENTS;
D O I
10.1016/j.jadohealth.2017.07.020
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
Purpose: The objectives of this study were to measure the impact of a behavioral economic intervention on human papillomavirus (HPV) vaccine initiation and series completion rates for adolescents and to measure the impact of the intervention on the receipt of a nonincentivized influenza vaccine. Methods: We conducted a quasi-randomized trial to compare the impact of an escalating delayed cash incentive (intervention), compared with usual care (control), on HPV vaccination initiation and series completion rates among adolescents (11-17 years) at an urban medical center. We measured HPV vaccine initiation and completion rates during the 12 months after enrollment and subsequent influenza vaccination rates for 24 months after enrollment. Results: A total of 85 participants were actively enrolled in the intervention arm and 103 were passively enrolled in the control arm. Participants were predominantly publically insured African-American and Hispanic adolescents. The majority (75%) of the intervention group received one or more doses of the HPV vaccine, with 36% completing the three-dose series, compared with 47% of the control group receiving one or more doses and only 13% completing the series. The odds of HPV p-value vaccine initiation (odds ratio 4.19 [95% confidence interval 1.84-10.10], p < .01) and HPV vaccine series completion (OR 4.16 [95% confidence interval 1.64-11.28], p < .01) were greater among the intervention group compared with the control group. There was no difference in influenza vaccination rates between the intervention group and the control group during the 20132014 season (p = .138) and during the 2014-2015 influenza season (p value .683). Conclusions: An incentive-based approach to HPV vaccination was effective in increasing vaccine initiation and series dose completion. (C) 2017 Society for Adolescent Health and Medicine. All rights reserved.
引用
收藏
页码:755 / 760
页数:6
相关论文
共 50 条
  • [31] Therapeutic Human Papillomavirus Vaccination
    Albers, Andreas E.
    Kaufmann, Andreas M.
    PUBLIC HEALTH GENOMICS, 2009, 12 (5-6) : 331 - 342
  • [32] Human papillomavirus vaccination in males
    Giuliano, Anna R.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : S24 - S26
  • [33] Human papillomavirus vaccination strategies
    Cachafeiro, Santiago Perez
    EMERGING INFECTIOUS DISEASES, 2007, 13 (12) : 1958 - 1959
  • [34] Vaccination against human papillomavirus
    Aubin, F.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2012, 139 (05): : 339 - 343
  • [35] Preventive human papillomavirus vaccination
    Lehtinen, M
    Dillner, J
    SEXUALLY TRANSMITTED INFECTIONS, 2002, 78 (01) : 4 - 6
  • [36] Monitoring of human papillomavirus vaccination
    Dillner, J.
    Arbyn, M.
    Unger, E.
    Dillner, L.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 163 (01): : 17 - 25
  • [37] Human papillomavirus vaccination for boys
    Quinn, Stephany
    Goldman, Ran D.
    CANADIAN FAMILY PHYSICIAN, 2015, 61 (01) : 43 - 46
  • [38] Update of human papillomavirus vaccination
    Kim, Byoung-Gie
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2015, 58 (04): : 313 - 318
  • [39] Vaccination against human papillomavirus
    Mello, Claudia Figueiredo
    EINSTEIN-SAO PAULO, 2013, 11 (04): : 547 - 549
  • [40] Vaccination against human papillomavirus
    Hillemanns, Peter
    Kampers, Johanna
    Hachenberg, Jens
    Jentschke, Matthias
    INTERNIST, 2021, 62 (08): : 816 - 826